×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
All
Acquired Podcast: The Scientific Journey Behind Ozempic
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
FDA Approves Wegovy for MASH Treatment
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Novo Nordisk Advances Semaglutide in MASH Treatment Following ESSENCE Trial Success
Novo Nordisk Ends Partnership with Hims & Hers Over Safety Concerns
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Expands $499 Wegovy® Offer to Retail Pharmacies
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novo Nordisk's Stance on Semaglutide for Cosmetic Use
Ozempic Linked to Reduced Tobacco-Related Healthcare Needs
Ozempic® Shows New Benefit for People with Type 2 Diabetes and PAD
Possible Link Between Semaglutide and Vision Loss Raises Questions
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
Semaglutide 7.2 mg Demonstrates Greater Weight Loss but Faces Market Challenges
Semaglutide's Breakthrough in Kidney Disease Management
Sustained Weight Loss and Cardiovascular Risk Reduction with Wegovy
The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
Page 1 of 2
1
2
Articles
Articles
All News
News
October 2025
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
September 2025
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Dexcom Introduces Smart Basal at EASD 2025
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
CVS Caremark Faces Lawsuit Over Dropping Zepbound
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
August 2025
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
Teva Launches First Generic GLP-1 for Obesity
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Signos Press Release Raises Questions About FDA Clearance Claims
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
FDA Approves Wegovy for MASH Treatment
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
July 2025
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
